anticorps ACVRL1, anticorps vgb, anticorps alk1, anticorps zehn1109, anticorps hm:zehn1109, anticorps ACVRLK1, anticorps ALK-1, anticorps ALK1, anticorps HHT, anticorps HHT2, anticorps ORW2, anticorps SKR3, anticorps TSR-I, anticorps R-3, anticorps R3, anticorps SETHKIR, anticorps AI115505, anticorps AI427544, anticorps Acvrlk1, anticorps Alk1, anticorps activin A receptor like type 1, anticorps activin A receptor type II-like 1, anticorps activin A receptor, type II-like 1, anticorps ACVRL1, anticorps acvrl1, anticorps Acvrl1
Sujet
ALK-1 or Activin receptor-like kinase-1 is a type I cell surface receptor for the TGF-beta (transforming growth factor-beta) super family of proteins. It is expressed predominantly in endothelial cells with moderate expression in smooth muscle cells, myofibroblast, hepatic stellate cells, chondrocytes, monocytes, myoblasts, macrophages and fibroblasts. ALK-1 plays a pivotal role in vascular remodelling and angiogenesis. More specifically its key function is in arterial/venous differentiation during embryonic vascular development. Mutations in ALK-1 gene (12q11-14) causes HHT2 (Hereditary Haemorrhagic Telangiectasia type 2), an autosomal dominant multisystem vascular dysplasia caused by a haploinsufficiency mechanism.